Sunshine Lake Pharma Signs AI Drug R&D Framework with Shenzhen XtalPi

MT Newswires Live
01/27

Sunshine Lake Pharma (HKG:6887) said it has entered into a cooperation framework agreement with Shenzhen XtalPi Technology to pursue a joint venture focused on AI-driven drug research and development, according to a Monday Hong Kong bourse filing.

Shares of the pharmaceutical firm were up over 3% in Tuesday morning trade.

The parties plan to build an AI drug R&D platform, including a joint laboratory for innovative drug discovery, joint development of AI large models across the drug development lifecycle, and the creation of a "Model-as-a-Service" business model, the filing showed.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10